Dr Yihong Wang, MD | |
593 Eddy St, Apc 12, Providence, RI 02903-4923 | |
(401) 444-9897 | |
(401) 444-8514 |
Full Name | Dr Yihong Wang |
---|---|
Gender | Female |
Speciality | Pathology |
Experience | 30 Years |
Location | 593 Eddy St, Providence, Rhode Island |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649439142 | NPI | - | NPPES |
MD13830 | Other | RI | MEDICAL LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | MD13830 (Rhode Island) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Rhode Island Hospital | Providence, RI | Hospital |
The Miriam Hospital | Providence, RI | Hospital |
Newport Hospital | Newport, RI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Newport Hospital | 0042111437 | 34 |
The Miriam Hospital | 6901796408 | 186 |
Rhode Island Hospital | 8921900044 | 303 |
News Archive
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.
AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.
› Verified 3 days ago
Entity Name | Newport Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063632180 PECOS PAC ID: 0042111437 Enrollment ID: O20040422000696 |
News Archive
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.
AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.
› Verified 3 days ago
Entity Name | Rhode Island Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1154537520 PECOS PAC ID: 8921900044 Enrollment ID: O20141017000105 |
News Archive
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.
AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.
› Verified 3 days ago
Entity Name | The Miriam Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1598978744 PECOS PAC ID: 6901796408 Enrollment ID: O20170303000645 |
News Archive
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.
AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Yihong Wang, MD 593 Eddy St, Apc 12, Providence, RI 02903-4923 Ph: (401) 444-9897 | Dr Yihong Wang, MD 593 Eddy St, Apc 12, Providence, RI 02903-4923 Ph: (401) 444-9897 |
News Archive
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.
AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October.
› Verified 3 days ago
Dr. Ga Hie Nam, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5057 Fax: 401-444-8514 | |
N Peter Libbey, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 825 Chalkstone Ave, Roger Williams Medical Center/pathology Dept., Providence, RI 02908 Phone: 401-456-2162 Fax: 401-456-2131 | |
Sara Maleki, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 12, Providence, RI 02903 Phone: 401-444-8515 Fax: 401-444-8514 | |
Mirfrida Geller, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-8450 Fax: 401-444-5088 | |
Dr. Lisa Goldstein, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Department Of Pathology, Providence, RI 02906 Phone: 401-793-4246 Fax: 401-274-5154 | |
Dr. Gladys Telang, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 10, Providence, RI 02903 Phone: 401-444-7959 Fax: 401-444-7144 | |
Xin He, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-4923 |